A groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

Enormous progress has been made in tackling the global HIV epidemics over the past two decades. The number of people dying ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

US funding to fight HIV/AIDS has saved 26 million lives since 2003, with the greatest benefits felt in sub-Saharan Africa ...

Researchers from Imperial College London, working with the University of Oxford and Rockefeller University, have shown ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Yearly doses could reduce barriers people face to taking preventative HIV medication, researchers said. An annual jab to ...